Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Parts of New York state faced up to five feet of snow over the last few days and more is coming across the Great Lakes region ...
Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.
Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback